ENTEROSGEL is an oral intestinal adsorbent (enterosorbent).
Menu
Standard and tracking shipping to UK
It is based on a mineral (organosilicon compound: polymethylsiloxane polyhydrate) with adsorption capacity towards some toxic and harmful substances in the gut (e.g. endotoxins, enterotoxins), physically binding them to its surface, with the intention of reducing stool frequency and duration of diarrhoea.
ENTEROSGEL has several unique features
Both hydrophilic (-OH) and hydrophobic (-CH3) surface groups, so can adsorb both hydrophobic and hydrophilic molecules.
A hydrogel with a unique porous structure consisting of small micropores and a majority of larger mesopores suitable for adsorption of toxins.
These properties favour ENTEROSGEL’S® adsorption of toxins and limit adsorption of lower molecular mass solutes such as pharmaceutical drugs.
ENTEROSGEL is a drug free alternative that has been very widely used in many countries, with no reports of adverse effects. Its safety and performance has been confirmed in numerous clinical investigations where over three thousand patients have been treated with ENTEROSGEL.
LAB BASED STUDIES
A recent article published in the Nature journal “Scientific Reports” has demonstrated that ENTEROSGEL can adsorb (bind) bacterial toxins and bile acids which could help treat tummy bugs and IBS. The study tested the adsorption of bacterial toxins released from Clostridium difficile, Shigella and E.coli, which can cause inflammation and damage to the mucosal cells lining the colon resulting in diarrhoea. Also tested were common bile acids; the levels of which can be raised in the intestines of patients with IBS. ENTEROSGEL adsorption of these molecules was compared to an activated carbon which is used orally to treat cases of poisoning and occasionally other conditions such as diarrhoea. The results showed that ENTEROSGEL has substantial adsorption or binding capacity for these bacterial toxins and to a lesser extent the most common bile acids.
CLINICAL TRIALS
A 2018 randomised controlled clinical study investigating ENTEROSGEL use in acute diarrhoea, recruited 105 patients from ten GP surgeries across England. Patients were randomised to the treatment group which received ENTEROSGEL and oral rehydration solution for 8 days, or the control group which received oral rehydration solution alone. Patients completed a daily diary to record their symptoms and treatment use. The study found that the duration of diarrhoea was significantly shorter in the group of patients receiving ENTEROSGEL compared to the control group. ENTEROSGEL was found to be well tolerated and safe with no serious side effects and is published in the BMJ Open Gastroenterology journal.
When used to treat chronic diarrhoea associated with irritable bowel syndrome, ENTEROSGEL has been shown to lead to normalisation of stool frequency and decrease of abdominal pain.
A 2016 clinical study investigated Enterosgel use in the prevention of gastrointestinal adverse reactions in 90 patients with uterine or cervical cancer, treated by external pelvic radiotherapy. Compared to patients who weren’t taking Enterosgel, patients in Enterosgel group had less diarrhoea and nausea and lower weight loss. Suggesting Enterosgel could be recommended as a supportive treatment during pelvic radiation, because it is well tolerated and effectively reduces gastrointestinal problems and weight loss.
If you would like to receive the clinical literature review about Enterosgel, please drop us a quick email to research@enteromed.co.uk.
Please, give me access to the Clinical Information about Enterosgel